tickrz reports
tickrz rank
D
Illumina Inc (ILMN)
Healthcare | Drugs
209.35  -0.63%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 403Warren Buffett RankC / 289
Pure Value RankD / 467Dividend RankD / NO DIVIDEND
Moat RankA / 47Financial Strength RankA / 29
Growth RankA / 22Momentum RankC / 274
ILMN vs DRUGS SECTOR & S&P 500
VALUATION
ILMNSECTORS&P 500
P/E RATIO41.4335.719.28
EV/EBITDA RATIO26.8425.111.77
P/S RATIO12.467.12.03
P/B RATIO11.418.73.09
QUALITY
RETURN ON EQUITY27.86%16.98%13.82%
RETURN ON CAPITAL19.22%26.23%10.04%
NET MARGIN18.93%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATIO0.46%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY42%
INTEREST COVERAGE17.58x
CURRENT RATIO3.88
GROWTH
5 YR EPS GROWTH37.7%
5 YR SPS GROWTH17.84%
5 YR BPS GROWTH11.27%
About tickrz
Key Concepts
Great Investors
Illumina Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank D / 403
Illumina Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 467Warren Buffett ranking C / 289
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Illumina Inc's valuation score is comprised of a P/E ratio of 41.4x, a P/B ratio of 11.4x, a P/S ratio of 12.5x, and an EV/EBITDA ratio of 26.8x. Illumina Inc ranks 467 out of the S&P 500 constituents on valuation--a relatively weak score.Illumina Inc ranks 289 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Illumina Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

quality
moat A / 47financial strength A / 29
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Illumina Inc appears to have a durable competitive advantage within the Healthcare sector. Illumina Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.58x, a debt/equity ratio of 42% and a Moat Rank of 47 translate to a strong Financial Strength score.


momentum C / 274
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 10.85% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 274. Based on its 12 month stock performance, Illumina Inc will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Illumina Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 22
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 37.7% 5 year annualized EPS growth, 17.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 11.3% speak to its impressive growth ranking.

Illumina Inc (ILMN)
Healthcare | Drugs
209.35  -0.63%


tickrz rank
D
VALUATION RATIOS
P/E Ratio41.43x
P/B Ratio11.41x
P/S Ratio12.46x
EV/EBITDA Ratio26.84x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATIO0.46%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY42%
INTEREST COVERAGE17.58x
CURRENT RATIO3.88
MOAT
ROE27.86%
ROIC19.22%
Net Margin18.93%
GROWTH
5 YR EPS GROWTH37.7%
5 YR SPS GROWTH17.84%
5 YR BPS GROWTH11.27%

TICKRZ RANK
Illumina Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Illumina Inc's valuation score is comprised of a P/E ratio of 41.4x, a P/B ratio of 11.4x, a P/S ratio of 12.5x, and an EV/EBITDA ratio of 26.8x. Illumina Inc ranks 467 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Illumina Inc ranks 289 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Illumina Inc is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Illumina Inc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Illumina Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 17.58x, a debt/equity ratio of 42% and a Moat Rank of 47 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 10.85% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 274. Based on its 12 month stock performance, Illumina Inc will not appeal to momentum investors.

VALUE + YIELD
Illumina Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 37.7% 5 year annualized EPS growth, 17.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 11.3% speak to its impressive growth ranking.